An investigation for investors in Ocera Therapeutics Inc (NASDAQ:OCRX) shares over potential securities laws violations by Ocera Therapeutics was announced and NASDAQ:OCRX stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 02/09/2017 --An investigation was announced on behalf of investors in Ocera Therapeutics Inc shares over potential securities laws violations in connection certain financial statements.

Investors who purchased shares of Ocera Therapeutics Inc (NASDAQ:OCRX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ocera Therapeutics Inc (NASDAQ:OCRX) concerning whether certain statements regarding Ocera Therapeutics' business, its prospects and its operations were materially false and misleading at the time they were made.

Palo Alto, CA based Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on acute and chronic orphan liver diseases. On January 30, 2017, Ocera Therapeutics Inc reported the results of its Phase 2b study of Ornithine Phenylacetate were not statistically significant in terms of the primary and secondary endpoints.

Shares of Ocera Therapeutics Inc (NASDAQ:OCRX) declined to as low as $0.52 per share on February 7, 2017.

Those who purchased shares of Ocera Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com